The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies

Cancer Cell

Volumn 9, Issue 6, 2006, Pages 485-495

  Ji, Hongbin ^a   Li, Danan ^a   Chen, Liang ^a   Shimamura, Takeshi ^a   Kobayashi, Susumu ^b   McNamara, Kate ^a   Mahmood, Umar ^b   Mitchell, Albert ^c   Sun, Yangping ^c   Al Hashem, Ruqayyah ^c   Chirieac, Lucian R ^c   Padera, Robert ^c   Bronson, Roderick T ^b   Kim, William ^d   Jänne, Pasi A ^a,b   Shapiro, Geoffrey I ^a,b   Tenen, Daniel ^b   Johnson, Bruce E ^a,b   Weissleder, Ralph ^b   Sharpless, Norman E ^d   Wong, Kwok Kin ^a,b   more..

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

CELLCYCLE; PROTEINS; SIGNALING

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; HKI 272; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CANCER REGRESSION; CARCINOGENICITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SENSITIVITY; DRUG TARGETING; ENZYME INDUCTION; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL; LUNG CARCINOGENESIS; MOUSE; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

EID: 33744788136     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2006.04.022     Document Type: Article

References (45)

1. Adjei A.A. Targeting multiple signal transduction pathways in lung cancer. Clin. Lung Cancer 7 Suppl 1 (2005) S39-S44
2. Amann J., Kalyankrishna S., Massion P.P., Ohm J.E., Girard L., Shigematsu H., Peyton M., Juroske D., Huang Y., Stuart Salmon J., et al. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res. 65 (2005) 226-235
3. Arteaga C.L. ErbB-targeted therapeutic approaches in human cancer. Exp. Cell Res. 284 (2003) 122-130
4. Blagosklonny M.V. Gefitinib (iressa) in oncogene-addictive cancers and therapy for common cancers. Cancer Biol. Ther. 3 (2004) 436-440
5. Cappuzzo F., Hirsch F.R., Rossi E., Bartolini S., Ceresoli G.L., Bemis L., Haney J., Witta S., Danenberg K., Domenichini I., et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J. Natl. Cancer Inst. 97 (2005) 643-655
6. Cappuzzo F., Varella-Garcia M., Shigematsu H., Domenichini I., Bartolini S., Ceresoli G.L., Rossi E., Ludovini V., Gregorc V., Toschi L., et al. Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. J. Clin. Oncol. 23 (2005) 5007-5018
7. Engelman J.A., and Janne P.A. Factors predicting response to EGFR tyrosine kinase inhibitors. Semin. Respir. Crit. Care Med. 26 (2005) 314-322
8. Engelman J.A., Janne P.A., Mermel C., Pearlberg J., Mukohara T., Fleet C., Cichowski K., Johnson B.E., and Cantley L.C. ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc. Natl. Acad. Sci. USA 102 (2005) 3788-3793
9. Fisher G.H., Wellen S.L., Klimstra D., Lenczowski J.M., Tichelaar J.W., Lizak M.J., Whitsett J.A., Koretsky A., and Varmus H.E. Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev. 15 (2001) 3249-3262
10. Gazdar A.F., Shigematsu H., Herz J., and Minna J.D. Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers?. Trends Mol. Med. 10 (2004) 481-486
11. Giaccone G. Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer. J. Clin. Oncol. 23 (2005) 3235-3242
12. Greulich H., Chen T.H., Feng W., Janne P.A., Alvarez J.V., Zappaterra M., Bulmer S.E., Frank D.A., Hahn W.C., Sellers W.R., and Meyerson M. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med 2 (2005) e313
13. Hirata A., Hosoi F., Miyagawa M., Ueda S., Naito S., Fujii T., Kuwano M., and Ono M. HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells. Cancer Res. 65 (2005) 4253-4260
14. Hynes N.E., and Lane H.A. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer 5 (2005) 341-354
15. Janne P.A., Engelman J.A., and Johnson B.E. Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. J. Clin. Oncol. 23 (2005) 3227-3234
16. Ji H., Zhao X., Yuza Y., Shimamura T., Li D., Protopopov A., Jung B.L., McNamara K., Xia H., Glatt K.A., et al. Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. Proc. Natl. Acad. Sci. USA 103 (2006) 7817-7822
17. Kim C.F., Jackson E.L., Woolfenden A.E., Lawrence S., Babar I., Vogel S., Crowley D., Bronson R.T., and Jacks T. Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 121 (2005) 823-835
18. Kobayashi S., Boggon T.J., Dayaram T., Janne P.A., Kocher O., Meyerson M., Johnson B.E., Eck M.J., Tenen D.G., and Halmos B. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 352 (2005) 786-792
19. Kobayashi S., Ji H., Yuza Y., Meyerson M., Wong K.K., Tenen D.G., and Halmos B. An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. Cancer Res. 65 (2005) 7096-7101
20. Kwak E.L., Sordella R., Bell D.W., Godin-Heymann N., Okimoto R.A., Brannigan B.W., Harris P.L., Driscoll D.R., Fidias P., Lynch T.J., et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc. Natl. Acad. Sci. USA 102 (2005) 7665-7670
21. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., Harris P.L., Haserlat S.M., Supko J.G., Haluska F.G., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350 (2004) 2129-2139
22. Minna J.D., Peyton M.J., and Gazdar A.F. Gefitinib versus cetuximab in lung cancer: round one. J. Natl. Cancer Inst. 97 (2005) 1168-1169
23. Mitsudomi T., Kosaka T., Endoh H., Horio Y., Hida T., Mori S., Hatooka S., Shinoda M., Takahashi T., and Yatabe Y. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J. Clin. Oncol. 23 (2005) 2513-2520
24. Mukohara T., Engelman J.A., Hanna N.H., Yeap B.Y., Kobayashi S., Lindeman N., Halmos B., Pearlberg J., Tsuchihashi Z., Cantley L.C., et al. Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. J. Natl. Cancer Inst. 97 (2005) 1185-1194
25. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., Herman P., Kaye F.J., Lindeman N., Boggon T.J., et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304 (2004) 497-500
26. Pao W., Miller V., Zakowski M., Doherty J., Politi K., Sarkaria I., Singh B., Heelan R., Rusch V., Fulton L., et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. USA 101 (2004) 13306-13311
27. Pao W., and Miller V.A. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J. Clin. Oncol. 23 (2005) 2556-2568
28. Pao W., Miller V.A., Politi K.A., Riely G.J., Somwar R., Zakowski M.F., Kris M.G., and Varmus H. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2 (2005) e73
29. Pao W., Wang T.Y., Riely G.J., Miller V.A., Pan Q., Ladanyi M., Zakowski M.F., Heelan R.T., Kris M.G., and Varmus H.E. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2 (2005) e17
30. Perl A.K., Tichelaar J.W., and Whitsett J.A. Conditional gene expression in the respiratory epithelium of the mouse. Transgenic Res. 11 (2002) 21-29
31. Politi K., Zakowski M.F., Fan P.-D., Schonfeld E.A., Pao W., and Varmus H.E. Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev. (2006) 10.1101/gad.1417406 Published online May 16, 2006
32. Rabindran S.K., Discafani C.M., Rosfjord E.C., Baxter M., Floyd M.B., Golas J., Hallett W.A., Johnson B.D., Nilakantan R., Overbeek E., et al. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res. 64 (2004) 3958-3965
33. Riely G.J., Pao W., Pham D., Li A.R., Rizvi N., Venkatraman E.S., Zakowski M.F., Kris M.G., Ladanyi M., and Miller V.A. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin. Cancer Res. 12 (2006) 839-844
34. Seftor R.E., Seftor E.A., De Larco J.E., Kleiner D.E., Leferson J., Stetler-Stevenson W.G., McNamara T.F., Golub L.M., and Hendrix M.J. Chemically modified tetracyclines inhibit human melanoma cell invasion and metastasis. Clin. Exp. Metastasis 16 (1998) 217-225
35. Shigematsu H., Lin L., Takahashi T., Nomura M., Suzuki M., Wistuba I.I., Fong K.M., Lee H., Toyooka S., Shimizu N., et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J. Natl. Cancer Inst. 97 (2005) 339-346
36. Shigematsu H., Takahashi T., Nomura M., Majmudar K., Suzuki M., Lee H., Wistuba I.I., Fong K.M., Toyooka S., Shimizu N., et al. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res. 65 (2005) 1642-1646
37. Sordella R., Bell D.W., Haber D.A., and Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305 (2004) 1163-1167
38. Soung Y.H., Lee J.W., Kim S.Y., Seo S.H., Park W.S., Nam S.W., Song S.Y., Han J.H., Park C.K., Lee J.Y., et al. Mutational analysis of EGFR and K-RAS genes in lung adenocarcinomas. Virchows Arch. 446 (2005) 483-488
39. Sun Y., Schmidt N.O., Schmidt K., Doshi S., Rubin J.B., Mulkern R.V., Carroll R., Ziu M., Erkmen K., Poussaint T.Y., et al. Perfusion MRI of U87 brain tumors in a mouse model. Magn. Reson. Med. 51 (2004) 893-899
40. Suzuki M., Shigematsu H., Hiroshima K., Iizasa T., Nakatani Y., Minna J.D., Gazdar A.F., and Fujisawa T. Epidermal growth factor receptor expression status in lung cancer correlates with its mutation. Hum. Pathol. 36 (2005) 1127-1134
41. Takano T., Ohe Y., Sakamoto H., Tsuta K., Matsuno Y., Tateishi U., Yamamoto S., Nokihara H., Yamamoto N., Sekine I., et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J. Clin. Oncol. 23 (2005) 6829-6837
42. Tonon G., Wong K.K., Maulik G., Brennan C., Feng B., Zhang Y., Khatry D.B., Protopopov A., You M.J., Aguirre A.J., et al. High-resolution genomic profiles of human lung cancer. Proc. Natl. Acad. Sci. USA 102 (2005) 9625-9630
43. Tracy S., Mukohara T., Hansen M., Meyerson M., Johnson B.E., and Janne P.A. Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255. Cancer Res. 64 (2004) 7241-7244
44. Tsuchihashi Z., Khambata-Ford S., Hanna N., and Janne P.A. Responsiveness to cetuximab without mutations in EGFR. N. Engl. J. Med. 353 (2005) 208-209
45. Zhang G.J., Safran M., Wei W., Sorensen E., Lassota P., Zhelev N., Neuberg D.S., Shapiro G., and Kaelin Jr. W.G. Bioluminescent imaging of Cdk2 inhibition in vivo. Nat. Med. 10 (2004) 643-648